CHI to Host Inaugural Cellular Tumor Models for Drug Discovery Conference

NEEDHAM, Mass. - July 8, 2013 - PRLog -- Cambridge Healthtech Institute (CHI) announces its Inaugural Physiologically-Relevant Cellular Tumor Models for Drug Discovery conference to take place on October 29-30, 2013 at Le Meridien Cambridge-MIT in Cambridge, MA, and will focus on the latest advances in 3-D cellular tumor models and complex co-culture systems for functional analysis studies and compound screening/characterization.

Speakers include:

Omar S. Aljitawi, M.D., Assistant Professor, Internal Medicine, University of Kansas Medical Center

Anne Bang, Ph.D., Director, Cell Biology, Sanford-Burnham Medical Research Institute

Geoffrey A. Bartholomeusz, Ph.D., Assistant Professor and Director, siRNA Core Facility, Department of Experimental Therapeutics, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center

Mohanraj Dhanabal, Ph.D., Group Leader, Lead Discovery Technology, EMD Serono

Eugen Dhimolea, Ph.D., Research Fellow, Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School

Marina Fitzek, Associate Principal Scientist, Discovery Sciences, AstraZeneca

Sharon Gerecht, Ph.D., Associate Professor, Chemical and Biomolecular Engineering, Johns Hopkins University

Bumsoo Han, Ph.D., Associate Professor, Mechanics and Biomedical Engineering, Purdue University

Mitchell Ho, Ph.D., Chief, Antibody Therapy Section, Laboratory of Molecular Biology, National Cancer Institute, NIH

Laurence Lafanechere, Ph.D., CNRS Research Director, Department of Cell Differentiation and Transformation, Institut Albert Bonniot

Ray Mattingly, Ph.D., Professor, Pharmacology, Wayne State University

Aaron Morris, Ph.D., Lab Head, Cancer Biology, Sanofi Oncology

David Nolte, Ph.D., Professor, Physics, Purdue University

Michelle Palmer, Ph.D., Director, Discovery and Preclinical Research, Broad Institute

Nathalie Picollet-D’Hahan, Ph.D., Senior Researcher, CEA/DSV/iRTSV/BGE/Biomics

Fredika M. Robertson, Ph.D., Professor, Experimental Therapeutics, Center for Targeted Therapy, Transitional Therapeutics Laboratory, University of Texas MD Anderson Cancer Center

Caroline Shamu, Ph.D., Lecturer, Systems Biology and Director, ICCB-Longwood, Harvard Medical School

Adina Vultur, Ph.D., Staff Scientist, Wistar Institute

View the full agenda and register at http://www.fastcongress.com/cellular-tumor-models.

Writers and editors are invited to attend. To request a press pass, contact Lisa Scimemi, lscimemi@healthtech.com.

This conference is part of FAST: Functional Analysis & Screening Technologies Congress (Oct. 28-30).  
About Cambridge Healthtech Institute (chicorporate.com)

Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

Contact:
James Prudhomme
Cambridge Healthtech Institute
781-972-5400
jprudhomme@healthtech.com